Pacira Pharma (PCRX) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
February 24, 2022 8:00 AM ESTAnesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million More than 10 million patients have received EXPAREL since launch Conference call today at 8:30 a.m. ET
TAMPA, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2021.
The acquisition of Flexion Therapeutics combined with record EXPAREL sales resulted in... More
